Evaluation of a Lateral Flow Immunoassay COVIDTECH® SARS-CoV-2 IgM/IgG Antibody Rapid Test
Résumé
The new epidemic coronavirus SARS-CoV-2 is responsible for severe respiratory illness (i.e. COVID-19). RT-PCR is the gold standard in COVID-19 diagnosis and is performed on respiratory samples, while serological tests may contribute to diagnosis and permit seroprevalence studies. The lateral flow immunoassay (LFIA) PolyDTech simultaneously detects anti-SARS-CoV-2 IgM and IgG using a Sprotein recombinant antigen and has been independently evaluated in two laboratories. The specificity evaluated on 53 pre-pandemic samples reached 100% for IgM and IgG. Analyzing samples from patients with RT-PCR-confirmed infection, IgM/IgG antibodies were detected in 18/26 (69%)
Origine | Fichiers produits par l'(les) auteur(s) |
---|